Thus, SLLP1 represents a promising target for the immunotherapy of MM and, hopefully, our combined findings will lead to the development of effective immunotherapeutic approaches for patients with this fatal hematologic malignancy. The gene discussed is SPACA3; the disease is hematologic disorder.